Shots:
The P-II (AXIOMATIC-SSP) study evaluated milvexian (FXIa inhibitor) vs PBO in a ratio (2:1) in 2366 patients with new symptomatic ischemic stroke or new covert brain infarction who received aspirin & clopidogrel, following an acute ischemic stroke or TIA
The results showed a 30% relative risk reduction in recurrent symptomatic ischemic strokes in patients who received 25/50/100mg, BID & a dose-response was not observed, no fatal bleeding with no increase in symptomatic intracranial hemorrhage who received 21 days of dual antiplatelet therapy, followed by single antiplatelet therapy
The rate of major bleeding for 25mg, qd & BID was similar to PBO. The company is expected to initiate the P-III study in 2023
Ref: Businesswire | Image: BMS
